S
Sarah Laurent
Researcher at University of Cologne
Publications - 6
Citations - 354
Sarah Laurent is an academic researcher from University of Cologne. The author has contributed to research in topics: Multiple sclerosis & Neurology. The author has an hindex of 4, co-authored 5 publications receiving 196 citations.
Papers
More filters
Journal ArticleDOI
A systematic review of neurological symptoms and complications of COVID-19.
Xiangliang Chen,Xiangliang Chen,Sarah Laurent,Oezguer A. Onur,Oezguer A. Onur,Nina N. Kleineberg,Nina N. Kleineberg,Gereon R. Fink,Gereon R. Fink,Finja Schweitzer,Clemens Warnke +10 more
TL;DR: Headache, dizziness, taste and smell dysfunctions, and impaired consciousness were the most frequently described neurological symptoms, the latter more often among patients with a severe or critical disease course.
Journal ArticleDOI
Immunological Aspects of Approved MS Therapeutics.
Paulus S. Rommer,Ron Milo,May H. Han,Sammita Satyanarayan,Johann Sellner,Larissa Hauer,Zsolt Illes,Clemens Warnke,Sarah Laurent,Martin S. Weber,Yinan Zhang,Olaf Stüve +11 more
TL;DR: The objective of this review is to present the modes of action of these drugs and their effects on the immunopathogenesis of MS and each agent's clinical development and potential side effects are discussed.
Journal ArticleDOI
Age and the risks of high-efficacy disease modifying drugs in multiple sclerosis.
Finja Schweitzer,Sarah Laurent,Gereon R. Fink,Gereon R. Fink,Michael Barnett,Stephen W. Reddel,Hans-Peter Hartung,Clemens Warnke +7 more
TL;DR: This article reviews the risks of high-efficacy DMTs in MS with a specific focus on age-related efficacy and risks, including opportunistic infections, malignancies, and autoimmune reactions.
Journal ArticleDOI
Effects of disease-modifying therapy on peripheral leukocytes in patients with multiple sclerosis
Finja Schweitzer,Sarah Laurent,Gereon R. Fink,Gereon R. Fink,Michael Barnett,Hans-Peter Hartung,Clemens Warnke +6 more
TL;DR: This review summarizes the predicted and intended as well as unwanted adverse effects on leukocytes in peripheral blood as a result of treatment with DMTs for MS and links changes in laboratory tests to the possible therapeutic risks that include secondary autoimmunity, infections, and impaired response to vaccinations.
Posted ContentDOI
Neurological manifestations of COVID-19: A systematic review
Xiangliang Chen,Sarah Laurent,Oezguer A. Onur,Nina N. Kleineberg,Gereon R. Fink,Finja Schweitzer,Clemens Warnke +6 more
TL;DR: The most frequent neurological symptoms reported in association with COVID-19 are non-specific for the infection with SARS-CoV-2, and standardized international registries are needed to clarify the clinical relevance of the neuropathogenicity of Sars-Cov-2.